New pieces added to the molecular puzzle of rheumatoid arthritis

February 25, 2020

Walter and Eliza Hall Institute researchers have revealed new details about how joint inflammation evolves in rheumatoid arthritis, and the cells that prolong the inflammatory attack.

In both laboratory models and human clinical samples, the research team pinpointed immune cells called natural killer (NK) cells as an unexpected source of the inflammatory protein GM-CSF in rheumatoid arthritis, the first clue that these cells contribute to inflammatory autoimmune diseases. The research also explained how GM-CSF signals to other immune cells to prolong joint inflammation, and how GM-CSF signalling to immune cells is kept in check in healthy joints.

These discoveries could indicate potential new therapeutic targets for reducing joint inflammation in rheumatoid arthritis, and could potentially reduce inflammation in other autoimmune disease such as multiple sclerosis.

The research was published in the Journal of Experimental Medicine by a team co-led by Professor Ian Wicks, Professor Nicholas Huntington and Dr Cynthia Louis, with Dr Fernando Souza-Fonseca-Guimaraes.

At a glanceA surprising source of GM-CSF

Rheumatoid arthritis is a chronic inflammatory autoimmune disease in which the immune system mistakenly attacks joints and other tissues, causing inflammation, pain and long-term joint damage.

GM-CSF was originally discovered at the Walter and Eliza Hall Institute as a growth factor for blood cells, but it is increasingly recognised as a key inflammatory mediator that drives a number of autoimmune diseases.

Professor Wicks said that his team's earlier research, together with colleagues at the University of Melbourne, had identified the signalling protein GM-CSF as an important contributor to joint inflammation in rheumatoid arthritis. "When we removed GM-CSF, we could see a reduction in inflammation. This finding underpinned the development and current clinical trials of inhibitors of GM-CSF signalling as a new approach to treating rheumatoid arthritis," he said.

"Although we knew that GM-CSF signalling was important in joint inflammation, which cells were producing GM-CSF within joints, and how this protein signalled after binding to its receptor on other immune cells, was not well understood."

Dr Louis said the team discovered that GM-CSF in inflamed arthritis joints was produced by immune cells called natural killer (NK) cells. "This was a surprise because, until now, NK cells were thought to primarily be important for clearing virus-infected or cancer cells," she said. "This is the first time NK cells have been found to contribute to tissue inflammation in autoimmune diseases such as rheumatoid arthritis.

"As well as looking at our laboratory model of arthritis, we examined cells from the joints of people with rheumatoid arthritis and confirmed that NK cells are indeed a significant source of GM-CSF in patients.

"This discovery has solved one part of the puzzle about how inflammation occurs in rheumatoid arthritis," Dr Louis said.

Filling in the gaps

The team revealed that the protein CIS is important for 'switching off' GM-CSF signalling, a critical mechanism to restrain destructive inflammation in arthritis.

"In the absence of CIS, we saw hyperactivation of GM-CSF signalling and more severe arthritis," Dr Louis said.

"This research showed that if a new drug that mimics CIS were to be developed, it may help to reduce the debilitating effects of GM-CSF in rheumatoid arthritis, but also in other inflammatory diseases driven by GM-CSF, such as multiple sclerosis."

Professor Wicks said the research revealed new aspects of cell signalling that warranted further investigation. "We're very excited to have progressed our understanding of rheumatoid arthritis and potentially other inflammatory diseases," he said.
-end-
Professor Wicks is joint head of Clinical Translation at the Walter and Eliza Hall Institute and head of Rheumatology at The Royal Melbourne Hospital. Professor Huntington is now at Monash University's Biomedicine Discovery Institute and Dr Souza-Fonseca-Guiamares is now at the University of Queensland Diamantina Institute.

The research was supported by the Australian National Health and Medical Research Council, John T Reid Charitable Trusts and Victorian Government. Scientists involved in the research were also supported by the National Breast Cancer Foundation, Cure Cancer Australia, Harry J Lloyd Charitable Trust, Melanoma Research Alliance, Tour de Cure, Cancer Research Institute and Ian Potter Foundation.

Walter and Eliza Hall Institute

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.